AIIMS Bhopal claims substantial progress in drug trial for COVID-19 treatment
A senior official of All India Institute of Medical Sciences (AIIMS), Bhopal has claimed that the institute achieved substantial progress in drug trial for treatment of coronavirus infection.
The Institute had been conducting trials of the drug Mycobacterium W (Mw) COVID-19 patients at AIIMS Bhopal for the last few days, said the official.
“So far, three COVID-19 patients have recovered after the clinical trial of Mycobacterium W (Mw) at AIIMS,” told Dr Sarman Singh, Director, AIIMS Bhopal as per a PTI report.
The trials were being run for the last few days and the results were good, as out of four patients enrolled for the trial, three had fully recovered and discharged, he said.
If Mycobacterium W proves effective during the clinical trial, it will be used in the treatment of COVID-19, he further said.
Mycobacterium W was used in the treatment of leprosy and recently, the Council for Scientific and Industrial Research (CSIR) has tied up with Cadila Pharmaceuticals to evaluate the effect of this medicine for faster recovery of hospitalised COVID-19 patients, informed Singh.
Drug Controller of India has granted permission to conduct tests on critically ill COVID-19 patients at three major hospitals in the country including AIIMS Bhopal.
post_id:
uld_count:
Cookie not set
Like
Dislike
Value 1: 0
Value 2: 10
